Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

被引：32

作者：

Kunikane H. ^{[1
]}

Watanabe K. ^{[1
]}

Fukuoka M. ^{[2
]}

Saijo N. ^{[3
]}

Furuse K. ^{[4
]}

Ikegami H. ^{[5
]}

Ariyoshi Y. ^{[6
]}

Kishimoto S. ^{[7
]}

机构：

[1] Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Hodogaya-ku, Yokohama 240-8555

[2] Fourth Department of Internal Medicine, Kinki University, School of Medicine, Osaka-sayama

[3] Department of Medical Oncology and Radiation Oncology, National Cancer Center Central Hospital, Tokyo

[4] Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Sakai

[5] Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

[6] Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki

[7] Osaka Prefectural Habikino Hospital, Habikino

来源：

International Journal of Clinical Oncology | 2001年 / 6卷 / 6期

关键词：

Anemia; Chemotherapy; Erythropoietin; Non-small cell lung cancer; Randomized control trial;

D O I：

10.1007/s10147-001-8031-y

中图分类号：

学科分类号：

摘要：

Background. We studied the clinical effect of recombinant human erythropoietin (r-huEPO) on anemia induced by two courses of cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods. Seventy-two patients with NSCLC were randomized into three groups, receiving 100, or 200 IU/kg of r-huEPO, or placebo. The r-huEPO and placebo were administered subcutaneously three times a week for 6 weeks, starting 2 weeks after the initiation of chemotherapy. Results. In the 53 evaluable patients, hemoglobin (Hb) levels at the nadir after the second cycle of chemotherapy were significantly elevated compared with the nadir after the first cycle in both r-huEPO treated groups, while this level was decreased in the placebo group. Hb levels at the end of the second course of chemotherapy (week 8) in both r-huEPO groups were higher than that in the placebo groups. No adverse drug reaction attributable to r-huEPO was observed. Serum erythropoietin levels after the administration of r-huEPO were higher than those after placebo administration. Conclusions. r-huEPO had an effect in preventing anemia in patients with NSCLC who had cisplatin-based chemotherapy.

引用

页码：296 / 301

页数：5

共 24 条

[1]

Miller C.B., Jones R.J., Piantadosi S., Et al., Decreased erythropoietin response in patients with the anemia of cancer, N Engl J Med, 322, pp. 1689-1695, (1990)

[2]

Schapira L., Antin J.H., Ransil B.J., Et al., Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy, Blood, 76, pp. 2354-2359, (1990)

[3]

Oster W., Herrman F., Gamm H., Et al., Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration, J Clin Oncol, 8, pp. 956-962, (1990)

[4]

Birgegard G., Wide L., Simonsson B., Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation, Br J Haematol, 72, pp. 462-466, (1989)

[5]

Cerruti A., Castello G., Balleari E., Et al., Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin, Exp Hematol, 22, pp. 1261-1263, (1994)

[6]

Hyman N.H., Foster R.S., DeMeules J.E., Costanza M.C., Blood transfusions and survival after lung cancer resection, Am J Surg, 149, pp. 502-507, (1985)

[7]

Okamoto H., Saijo N., Shinkai T., Et al., Chemotherapy-induced anemia in patients with primary lung cancer, Ann Oncol, 3, pp. 819-824, (1992)

[8]

Spivak J.K., The mechanisms of action of erythropoietin, Int J Cell Cloning, 4, pp. 139-166, (1986)

[9]

Miller C.B., Platanias L., Mills S.R., Et al., Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia, J Natl Cancer Inst, 84, pp. 98-103, (1992)

[10]

Case D.C., Bukowski M., Carey R.W., Et al., Recombinant human erythropoietin therapy for anemic patients on combination chemotherapy, J Natl Cancer Inst, 85, pp. 801-806, (1993)

← 1 2 3 →